Literature DB >> 8321529

Holmium laser sclerectomy. Success and complications.

J S Schuman1, W G Stinson, B T Hutchinson, A R Bellows, C A Puliafito, R Lytle.   

Abstract

PURPOSE: To investigate the safety and efficacy of holmium YAG laser sclerectomy, a new laser filtration procedure.
METHODS: The authors performed holmium YAG laser sclerectomy on 49 eyes of 46 patients (mean follow-up, 12.3 +/- 1.1 months).
RESULTS: Mean preoperative intraocular pressure (IOP) was 26.9 +/- 1.3 mmHg; postoperative mean IOP on last follow-up visit was 19.7 +/- 1.6 mmHg. Thirty (61%) of 49 eyes achieved a final IOP of 5 to 22 mmHg, 29 (59%) of 49 had a final IOP of 5 to 19 mmHg, and 21 (43%) of 49 had a final IOP of 5 to 15 mmHg. Sixteen (73%) of 22 eyes treated postoperatively with 5-fluorouracil (5-FU) had a final IOP of 21 mmHg or less. Twenty-seven percent of eyes lost one or more lines of vision, and 36% of eyes gained one or more lines of vision; there was no median change in visual acuity. Complications included suprachoroidal hemorrhage in 7 (14%) of 49 eyes and intraoperative vitreous hemorrhage in 2. Seventeen (35%) of 49 eyes required a second IOP-lowering procedure.
CONCLUSION: Holmium YAG laser sclerectomy is an effective means to perform glaucoma filtration surgery. This is a full-thickness filtering procedure, with all of the risks attendant.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321529     DOI: 10.1016/s0161-6420(93)31538-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  2 in total

1.  Er:YAG laser-assisted filtration surgery: initial results in rabbits.

Authors:  Noa Kapelushnik; Ari Leshno; Reut Singer; Ruth Huna-Baron; Yaniv Barkana; Alon Skaat
Journal:  BMC Ophthalmol       Date:  2021-05-20       Impact factor: 2.209

2.  193 nm excimer laser sclerostomy in pseudophakic patients with advanced open angle glaucoma.

Authors:  B D Allan; P P van Saarloos; R L Cooper; I J Constable
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.